Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy

Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy

Abstract Cisplatin is a widely used chemotherapy drug, despite its significant ototoxic side effects. To date, the mechanism of cisplatin‐induced ototoxicity remains unclear, and hearing preservation during cisplatin‐based chemotherapy in patients is lacking. We found activation of the ATM‐Chk2‐p53...

Full description

Bibliographic Details
Main Authors: Nesrine Benkafadar, Julien Menardo, Jérôme Bourien, Régis Nouvian, Florence François, Didier Decaudin, Domenico Maiorano, Jean‐Luc Puel, Jing Wang
Format: Article
Language:English
Published: Springer Nature 2017-01-01
Series:EMBO Molecular Medicine
Subjects:
chemotherapy
cisplatin ototoxicity
DNA damage
hearing loss
protection
Online Access:https://doi.org/10.15252/emmm.201606230

Internet

https://doi.org/10.15252/emmm.201606230

Similar Items